Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021942 | 0.85 | FAAH (0.35) | FAAHSCN9A | |
| SCHEMBL14920522 | 0.84 | FAAH (0.40) | FAAHESR1ESR2SCN9A | |
| SCHEMBL16021420 | 0.79 | MAPK14 (0.42) | AMY1AESR1ESR2HSP90AA1ERN1 | |
| SCHEMBL14920445 | 0.74 | MEN1 (0.39) | ESR1ESR2MAPK14 | |
| SCHEMBL14920351 | 0.74 | PIM1 (0.41) | — | |
| SCHEMBL14920203 | 0.72 | ESR1 (0.50) | ESR1ESR2HSP90AA1 | |
| SCHEMBL14933629 | 0.69 | FAAH (0.42) | FAAHSCN9ASCN5A | |
| SCHEMBL14920262 | 0.68 | DHODH (0.45) | SCN9ADHODHKCNH2SCN5A | |
| SCHEMBL29559851 | 0.64 | CRHBP (0.53) | AMY1AACLYERN1 | |
| SCHEMBL28718300 | 0.64 | CRHBP (0.53) | AMY1AACLYERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773641-B1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9481677-B2 | Biaryl ether sulfonamides and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-01 | — | — | US | disclosed |
| US-9365578-B2 | — | — | 2016-06-14 | — | — | US | disclosed |
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| EP-2773641-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256736-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPV3, TRPV2 | AMY1A 4425/4885FAAH 147/4885MCL1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.